SCHEMBL342937

SCHEMBL342937

CC(=O)N(Cc1ccccc1)CC(C)(C)C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
RIPK1 Q13546 2/20 0.42
ALDH1A1 P00352 3/20 0.41
MAN2A1 Q16706 1/20 0.41
MAN1B1 Q9UKM7 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 2/20 0.41
TSPO P30536 1/20 0.41
REN P00797 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13900616 0.83 LMNA (0.51) LMNARECQLMEN1KMT2AL3MBTL1
SCHEMBL2117209 0.79 LMNA (0.62) LMNAMEN1KMT2ATDP1CHRM2
SCHEMBL340999 0.77 CARM1 (0.46) LMNAMEN1KMT2AL3MBTL1HTT
SCHEMBL13178317 0.76 CTSS (0.52) LMNARECQLMEN1KMT2AL3MBTL1
SCHEMBL1059560 0.74 LMNA (0.56) LMNAMEN1KMT2ATDP1CHRM2
SCHEMBL3836681 0.74 LMNA (0.72) LMNAMEN1KMT2ACHRM2CHRM4
SCHEMBL340966 0.73 MEN1 (0.41) MEN1KMT2AL3MBTL1HTTRIPK1
SCHEMBL11378089 0.73 LMNA (0.55) LMNAMEN1KMT2ATDP1CHRM2
SCHEMBL7503719 0.72 LMNA (0.50) LMNAMEN1KMT2ATDP1CHRM2
SCHEMBL22035107 0.72 HDAC1 (0.52) LMNARECQLMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP claimed
CN-103261145-B There is the amine of secondary aliphatic amino group SIKA TECHNOLOGY AG (CH) 2016-04-13 CN claimed
EP-2651875-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-09-12 US claimed
CN-103261145-A Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG 2013-08-21 CN claimed
WO-2012080264-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465842-A1 Amines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
US-8157950-B2 Aldimine and composition containing aldimine SIKA TECHNOLOGY AG (CH) 2012-04-17 US claimed
US-20110253309-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2011-10-20 US claimed
EP-2194082-B1 Aldimine and composition comprising aldimine SIKA TECHNOLOGY AG (CH) 2011-09-07 EP claimed
EP-2194082-A1 Aldimine and composition comprising aldimine Sika Technology AG (CH) 2010-06-09 EP claimed
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP disclosed
EP-2414418-B1 COMPOSITION CURABLE IN TWO STAGES COMPRISING A SURFACE DEACTIVATED POLYISOCYANATE SIKA TECH AG (CH) 2017-08-09 EP disclosed
CN-103261145-B There is the amine of secondary aliphatic amino group SIKA TECHNOLOGY AG (CH) 2016-04-13 CN disclosed
US-9290603-B2 Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-03-22 US disclosed
EP-2236535-A1 Humidity curing polyurethane composition being accelerated by influence of heat Sika Technology AG (CH) 2010-10-06 EP disclosed
EP-2236533-A1 Heat curing or heat activatable composition comprising a surface deactivated polyisocyanate Sika Technology AG (CH) 2010-10-06 EP disclosed
EP-2236534-A1 Composition curable in two stages comprising a surface deactivated polyisocyanate Sika Technology AG (CH) 2010-10-06 EP disclosed
WO-2010063741-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2010-06-10 WO disclosed
EP-2194082-A1 Aldimine and composition comprising aldimine Sika Technology AG (CH) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS AAAS, PNMT, PARG LMNA 1183/4885RECQL 1013/4885MEN1 3165/4885
US-20110253309-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE ALDH7A1, ALDH3A1, ADH5 LMNA 343/4885RECQL 1359/4885MEN1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.